Clear aligner therapy maker Align Technology, Inc. (ALGN - Analyst Report) is well on track with its product enhancement process. Recently, the company announced the launch of its latest innovation within its Invisalign G-Series of products.
The latest breakthrough, termed by the company as Invisalign G7, includes a set of features that will facilitate better control of tooth movements along with improved treatment outcomes. This Invisalign G7 that addresses critical treatment finishing challenges, will remain particularly effective for teenage patients.
Invisalign G7 is based on Invisalign SmartStage technology that optimizes staging and sequence of tooth movements and aligner activation. Align claims this product will deliver better upper lateral control, improved root control, and features to address prevention of posterior open bites. In this regard, the company noted that Invisalign is the only system that combines proprietary SmartTrack material with SmartForce features and SmartStage technology for more predictable tooth movement than ever before.
Apart from Invisalign G7, Align also announced the launch of ClinCheck Pro 5.0, its next-generation Invisalign treatment software. This has the ability to view side-by-side treatment plans, a more realistic 3D visual model and a new configurable toolbar for greater flexibility. Both the Invisalign G7 features and the ClinCheck Pro 5.0 software will be available worldwide to Invisalign-trained providers on Oct 17, 2016.
Banking on its primary product, Invisalign Clear Aligner, Align has established itself as a strong player in the malocclusion market. Over the past few quarters, sales have increased consistently, riding on the strength of this product. Moreover, several features have been introduced across the Invisalign system, to address some of the most significant treatment challenges encountered by doctors. The company’s Invisalign G5 and G4 are working successfully in the global orthodontic market.
In addition, Invisalign Teen continues as the largest growth opportunity, being the prime orthodontic segment of Align on a global basis. In the key teen market, the company continues to gain considerable share. With the latest Invisalign G7 launch, we expect Align to further strengthen its position, particularly in the Invisalign Teen market.
Zacks Rank & Key Picks
Align Technology currently has a Zacks Rank #3 (Hold).
Some better-ranked medical stocks are Boston Scientific Corporation (BSX - Analyst Report) , The Cooper Companies Inc. (COO - Analyst Report) and Laboratory Corp. of America Holdings (LH - Analyst Report) . All the three stocks carry a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Boston Scientific has gained 25.6% year to date, much better than the S&P 500’s 4.5% over the same period. Over the past three months, BSX’s earnings estimates for the current year have inched up 0.9% to $1.10 per share.
Cooper has seen eight estimates move higher for the current fiscal over the past 60 days, compared to no downward movement. Accordingly, earnings estimates for the year have moved up by 1.2% to $8.42 per share. The stock recorded a gain of 33.9% year to date.
LabCorp has an impressive earnings growth rate of 11.3% for the current fiscal, way ahead of the industry growth expectation of 7.6%. Year to date, the stock has performed better than the S&P 500, with a gain of 10.4%.
Confidential from Zacks
Beyond this Analyst Blog, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>